Results 1 to 10 of about 187,605 (309)

Drug interactions in COVID-19 treatment. Systematic review [PDF]

Farmacja Polska, 2022
The COVID-19 pandemic has driven the experimental, off-label treatments with co-administration of supportive therapies for many patients with severe infections and coexisting chronic conditions. This situation has inevitably led to polypharmacy, which is
Arkadiusz Adamiszak, Tomasz Torliński, Edmund Grześkowiak, Alicja Bartkowska-Śniatkowska, Agnieszka Bienert   +4 more
doaj   +2 more sources

Analysis of the efficacy of Chinese medicine in the treatment of covid-19 and the study of medication pattern [PDF]

ITM Web of Conferences, 2022
In order to explore the efficacy and medication pattern of Chinese medicine in the treatment of COVID-19, we conducted statistics on the medication use of Chinese medicine based on some clinical data of novel coronavirus pneumonia (COVID-19) and related ...
Cong Xiaoqing, Ren Xiaoqiang
doaj   +1 more source

Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics

Pharmaceutics, 2021
Since coronavirus disease 2019 (COVID-19) is a serious new worldwide public health crisis with significant morbidity and mortality, effective therapeutic treatments are urgently needed.
Dan-Yang Liu, Jia-Chen Liu, Shuang Liang, Xiang-He Meng, Jonathan Greenbaum, Hong-Mei Xiao, Li-Jun Tan, Hong-Wen Deng   +7 more
doaj   +1 more source

Key Considerations for Phase 2 or 3 Clinical Study Design of Anti-Inflammatory Agent for COVID-19 Treatment

Frontiers in Pharmacology, 2022
Purpose: Current understanding of COVID-19 disease progression suggests a major role for the “cytokine storm” as an important contributor to COVID-19 mortality.
Yewon Park, Joo Young Na, Joo-Youn Cho, Jaeseong Oh, Su-jin Rhee   +4 more
doaj   +1 more source

Pharmacogenetics Approach for the Improvement of COVID-19 Treatment

Viruses, 2021
The treatment of coronavirus disease 2019 (COVID-19) has been a challenge. The efficacy of several drugs has been evaluated and variability in drug response has been observed.
Ingrid Fricke-Galindo, Ramcés Falfán-Valencia   +1 more
doaj   +1 more source

Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview

Pharmacology Research & Perspectives, 2021
Drug‐drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID‐19; i.e., chloroquine ...
Haleh Rezaee, Fariba Pourkarim, Samira Pourtaghi‐Anvarian, Taher Entezari‐Maleki, Touraj Asvadi‐Kermani, Masoud Nouri‐Vaskeh   +5 more
doaj   +1 more source

Drug repurposing against coronavirus disease 2019 (COVID-19): A review

Journal of Pharmaceutical Analysis, 2021
Since December 2019, severe acute respiratory syndrome coronavirus 2 has been found to be the culprit in the coronavirus disease 2019 (COVID-19), causing a global pandemic. Despite the existence of many vaccine programs, the number of confirmed cases and
Lianxiang Luo, Qin Qiu, Fangfang Huang, Kaifeng Liu, Yongqi Lan, Xiaoling Li, Yuge Huang, Liao Cui, Hui Luo   +8 more
doaj   +1 more source

Clinical experience of treatment of immunocompromised individuals with persistent SARS-CoV-2 infection based on drug resistance mutations determined by genomic analysis: a descriptive study

BMC Infectious Diseases, 2023
Background The efficacy of antiviral drugs that neutralize antibody drugs and fight against SARS-COV-2 is reported to be attenuated by genetic mutations of the virus in vitro.
Haruka Shimazu, Daiki Wada, Shuhei Maruyama, Akira Inoue, Masami Kashihara, Tomoyuki Yoshihara, Fukuki Saito, Kazuhisa Yoshiya, Yasushi Nakamori, Yasuyuki Kuwagata   +9 more
doaj   +1 more source

Drug eruption: A mimicker of Coronavirus disease-2019 rash

Turkderm Turkish Archives of Dermatology and Venereology, 2022
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infections can be associated with several cutaneous lesions, among which maculopapular rash is the most common.
Tülin Ergun, Ilkay Ergenç, Seda Seven, Dilek Seçkin, Elif Cömert Özer, Meryem Aktaş, Elif Tükenmez Tigen   +6 more
doaj   +1 more source

Dexamethasone mitigates remdesivir-induced liver toxicity in human primary hepatocytes and COVID-19 patients

Hepatology Communications, 2023
Background:. Coronavirus disease 2019 (COVID-19) is a global pandemic that has caused more than 600 million cases and over six million deaths worldwide.
Kaiyan Liu, Sydney Stern, Emily L. Heil, Linhao Li, Rula Khairi, Scott Heyward, Hongbing Wang   +6 more
doaj   +1 more source